{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:26:36Z","timestamp":1773422796870,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"28","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,16]],"date-time":"2017-05-16T00:00:00Z","timestamp":1494892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GlaxoSmithKline Biologicals SA"},{"name":"GSK"},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Protein Science"},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"GSK"},{"name":"GSK"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.vaccine.2017.05.018","type":"journal-article","created":{"date-parts":[[2017,5,20]],"date-time":"2017-05-20T20:46:51Z","timestamp":1495313211000},"page":"3564-3574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Lot-to-lot consistency, safety and immunogenicity of 3 lots of Haemophilus influenzae type b conjugate vaccine: results from a phase III randomized, multicenter study in infants"],"prefix":"10.1016","volume":"35","author":[{"given":"Nicola P.","family":"Klein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remon","family":"Abu-Elyazeed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Cornish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael L.","family":"Leonardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard B.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter E.","family":"Silas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley E.","family":"Grogg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meera","family":"Varman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Frenck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Cheuvart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaela","family":"Baine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline M.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten","family":"Leyssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narcisa","family":"Mesaros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumita","family":"Roy-Ghanta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.05.018_b0005","unstructured":"WHO position paper on Haemophilus influenzae type b (Hib) vaccination. Wkly Epidemiol Rec. 2013;88:413\u201326."},{"key":"10.1016\/j.vaccine.2017.05.018_b0010","unstructured":"WHO. Data and surveillance on Haemophilus influenzae type b (Hib). Available at: http:\/\/www.who.int\/immunization\/monitoring_surveillance\/burden\/vpd\/surveillance_type\/sentinel\/Hib\/en\/ [last accessed: 11 July 2016]."},{"key":"10.1016\/j.vaccine.2017.05.018_b0015","first-page":"1","article-title":"Prevention and control of Haemophilus influenzae type b disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Briere","year":"2014","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2017.05.018_b0020","first-page":"1318","article-title":"Interim recommendations for the use of Haemophilus influenzae type b (Hib) conjugate vaccines related to the recall of certain lots of Hib-containing vaccines (PedvaxHIB and Comvax)","volume":"56","author":"Centers for Disease Control and Prevention (CDC)","year":"2007","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2017.05.018_b0025","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1542\/peds.2012-0266","article-title":"Haemophilus influenzae type b disease and vaccine booster dose deferral, United States, 1998\u20132009","volume":"130","author":"Briere","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2017.05.018_b0030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3201\/eid1801.110336","article-title":"Modeling insights into Haemophilus influenzae type b disease, transmission, and vaccine programs","volume":"18","author":"Jackson","year":"2012","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.018_b0035","first-page":"1008","article-title":". Licensure of a Haemophilus influenzae type b (Hib) vaccine (Hiberix) and updated recommendations for use of Hib vaccine","volume":"58","author":"Centers for Disease Control and Prevention","year":"2009","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2017.05.018_b0040","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s004310051100","article-title":"Does concomitant injection of a combined diphtheria-tetanus-acellular pertussis - hepatitis B virus - inactivated polio virus vaccine influence the reactogenicity and immunogenicity of commercial Haemophilus influenzae type b conjugate vaccines?","volume":"158","author":"Usonis","year":"1999","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.vaccine.2017.05.018_b0045","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1086\/514741","volume":"28","author":"Halperin","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.018_b0050","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0264-410X(00)00231-0","article-title":"A new DTPa-HBV-IPV vaccine co-administered with Hib, compared to a commercially available DTPw-IPV\/Hib vaccine co-administered with HBV, given at 6, 10 and 14 weeks following HBV at birth","volume":"19","author":"Gylca","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.018_b0055","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1542\/peds.109.4.e58","article-title":"Safety and reactogenicity of a novel DTPa-HBV-IPV combined vaccine given along with commercial Hib vaccines in comparison with separate concomitant administration of DTPa, Hib, and OPV vaccines in infants","volume":"109","author":"Zepp","year":"2002","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2017.05.018_b0060","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2165\/0148581-200810060-00008","article-title":"DTaP-IPV\/Hib vaccine (Pentacel)","volume":"10","author":"Dhillon","year":"2008","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.vaccine.2017.05.018_b0065","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40272-013-0047-z","article-title":"13-valent pneumococcal conjugate vaccine: a review of its use in infants, children, and adolescents","volume":"15","author":"Plosker","year":"2013","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.vaccine.2017.05.018_b0070","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1586\/14760584.4.2.139","article-title":"PEDIARIX: clinical trials","volume":"4","author":"Yeh","year":"2005","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.05.018_b0075","unstructured":"ROTARIX\u2122 Package insert and product information. Available at: http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM133539.pdf [last accessed: 8 November 2016]."},{"key":"10.1016\/j.vaccine.2017.05.018_b0080","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1016\/S0264-410X(01)00240-7","article-title":"A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults","volume":"19","author":"Joines","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.05.018_b0085","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/infdis\/149.6.1034","article-title":"The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b","volume":"149","author":"Anderson","year":"1984","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.018_b0090","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/infdis\/147.6.1100","article-title":"The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b","volume":"147","author":"Kayhty","year":"1983","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.018_b0095","doi-asserted-by":"crossref","first-page":"418","DOI":"10.15585\/mmwr.mm6516a3","article-title":"Food and drug administration approval for use of Hiberix as a 3-dose primary Haemophilus influenzae type b (Hib) vaccination series","volume":"65","author":"Briere","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2017.05.018_b0100","doi-asserted-by":"crossref","first-page":"e1375","DOI":"10.1542\/peds.2009-2992","article-title":"Immunogenicity and safety of H influenzae type b-N meningitidis C\/Y conjugate vaccine in infants","volume":"127","author":"Bryant","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2017.05.018_b0105","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1586\/14760584.4.6.793","article-title":"A combined diphtheria, tetanus, five-component acellular pertussis, poliovirus and Haemophilus influenzae type b vaccine","volume":"4","author":"Black","year":"2005","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.05.018_b0110","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(99)04377-9","article-title":"Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis","volume":"354","author":"Eskola","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.05.018_b0115","unstructured":"LeBlanc R. Clinical Review-Hiberix. Efficacy supplement (STN 125347.231). Center for Biologics Evaluation and Research Food and Drug Administration; 2016. Available at: http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM482651.pdf [last accessed: 4 November 2016]."},{"key":"10.1016\/j.vaccine.2017.05.018_b0120","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1086\/524668","article-title":"Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody","volume":"46","author":"Lee","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.05.018_b0125","doi-asserted-by":"crossref","first-page":"e1062","DOI":"10.1542\/peds.2008-1059","article-title":"Coadministration of RIX4414 oral human rotavirus vaccine does not impact the immune response to antigens contained in routine infant vaccines in the United States","volume":"122","author":"Dennehy","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2017.05.018_b0130","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1440-1754.2007.01139.x","article-title":"DTPa-HBV-IPV vaccine for primary vaccination of infants","volume":"43","author":"Nolan","year":"2007","journal-title":"J Paediatr Child Health"},{"key":"10.1016\/j.vaccine.2017.05.018_b0135","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/INF.0b013e318233049d","article-title":"Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada","volume":"31","author":"Vanderkooi","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.05.018_b0140","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jpeds.2014.12.014","article-title":"Adverse events following Haemophilus influenzae type b vaccines in the Vaccine Adverse Event Reporting System, 1990\u20132013","volume":"166","author":"Moro","year":"2015","journal-title":"J Pediatr"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17306266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17306266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T15:18:39Z","timestamp":1584112719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17306266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":28,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0264410X17306266"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.05.018","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lot-to-lot consistency, safety and immunogenicity of 3 lots of Haemophilus influenzae type b conjugate vaccine: results from a phase III randomized, multicenter study in infants","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}